Results of the first nationwide cohort study of outcomes in dialysis and kidney transplant patients before and after vaccination for COVID-19.
COVID-19
hospitalization
mortality
observational study
renal replacement therapy
Journal
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
ISSN: 1460-2385
Titre abrégé: Nephrol Dial Transplant
Pays: England
ID NLM: 8706402
Informations de publication
Date de publication:
31 Oct 2023
31 Oct 2023
Historique:
received:
27
01
2023
medline:
2
11
2023
pubmed:
12
7
2023
entrez:
11
7
2023
Statut:
ppublish
Résumé
Patients on kidney replacement therapy (KRT) have been identified as a vulnerable group during the coronavirus disease 2019 (COVID-19) pandemic. This study reports the outcomes of COVID-19 in KRT patients in Sweden, a country where patients on KRT were prioritized early in the vaccination campaign. Patients on KRT between January 2019 and December 2021 in the Swedish Renal Registry were included. Data were linked to national healthcare registries. The primary outcome was monthly all-cause mortality over 3 years of follow-up. The secondary outcomes were monthly COVID-19-related deaths and hospitalizations. The results were compared with the general population using standardized mortality ratios. The difference in risk for COVID-19-related outcomes between dialysis and kidney transplant recipients (KTRs) was assessed in multivariable logistic regression models before and after vaccinations started. On 1 January 2020, there were 4097 patients on dialysis (median age 70 years) and 5905 KTRs (median age 58 years). Between March 2020 and February 2021, mean all-cause mortality rates increased by 10% (from 720 to 804 deaths) and 22% (from 158 to 206 deaths) in dialysis and KTRs, respectively, compared with the same period in 2019. After vaccinations started, all-cause mortality rates during the third wave (April 2021) returned to pre-COVID-19 mortality rates among dialysis patients, while mortality rates remained increased among transplant recipients. Dialysis patients had a higher risk for COVID-19 hospitalizations and death before vaccinations started {adjusted odds ratio [aOR] 2.1 [95% confidence interval (CI) 1.7-2.5]} but a lower risk after vaccination [aOR 0.5 (95% CI 0.4-0.7)] compared with KTRs. The COVID-19 pandemic in Sweden resulted in increased mortality and hospitalization rates among KRT patients. After vaccinations started, a distinct reduction in hospitalization and mortality rates was observed among dialysis patients, but not in KTRs. Early and prioritized vaccinations of KRT patients in Sweden probably saved many lives.
Sections du résumé
BACKGROUND
BACKGROUND
Patients on kidney replacement therapy (KRT) have been identified as a vulnerable group during the coronavirus disease 2019 (COVID-19) pandemic. This study reports the outcomes of COVID-19 in KRT patients in Sweden, a country where patients on KRT were prioritized early in the vaccination campaign.
METHODS
METHODS
Patients on KRT between January 2019 and December 2021 in the Swedish Renal Registry were included. Data were linked to national healthcare registries. The primary outcome was monthly all-cause mortality over 3 years of follow-up. The secondary outcomes were monthly COVID-19-related deaths and hospitalizations. The results were compared with the general population using standardized mortality ratios. The difference in risk for COVID-19-related outcomes between dialysis and kidney transplant recipients (KTRs) was assessed in multivariable logistic regression models before and after vaccinations started.
RESULTS
RESULTS
On 1 January 2020, there were 4097 patients on dialysis (median age 70 years) and 5905 KTRs (median age 58 years). Between March 2020 and February 2021, mean all-cause mortality rates increased by 10% (from 720 to 804 deaths) and 22% (from 158 to 206 deaths) in dialysis and KTRs, respectively, compared with the same period in 2019. After vaccinations started, all-cause mortality rates during the third wave (April 2021) returned to pre-COVID-19 mortality rates among dialysis patients, while mortality rates remained increased among transplant recipients. Dialysis patients had a higher risk for COVID-19 hospitalizations and death before vaccinations started {adjusted odds ratio [aOR] 2.1 [95% confidence interval (CI) 1.7-2.5]} but a lower risk after vaccination [aOR 0.5 (95% CI 0.4-0.7)] compared with KTRs.
CONCLUSIONS
CONCLUSIONS
The COVID-19 pandemic in Sweden resulted in increased mortality and hospitalization rates among KRT patients. After vaccinations started, a distinct reduction in hospitalization and mortality rates was observed among dialysis patients, but not in KTRs. Early and prioritized vaccinations of KRT patients in Sweden probably saved many lives.
Identifiants
pubmed: 37433606
pii: 7222920
doi: 10.1093/ndt/gfad151
pmc: PMC10615630
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2607-2616Subventions
Organisme : Westman Foundation
Organisme : Njurfonden
Organisme : Gelin Foundation
Organisme : European Union
Organisme : University of Milano-Bicocca
Commentaires et corrections
Type : CommentIn
Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of the ERA.
Références
MMWR Morb Mortal Wkly Rep. 2021 Jun 04;70(22):825-829
pubmed: 34081687
Lancet Reg Health Eur. 2021 Oct;9:100178
pubmed: 34318288
Acta Paediatr. 2020 Dec;109(12):2459-2471
pubmed: 32951258
Transplantation. 2022 Apr 1;106(4):821-834
pubmed: 34753894
N Engl J Med. 2020 Jun 18;382(25):2475-2477
pubmed: 32329975
Lakartidningen. 2021 Nov 16;118:
pubmed: 35502607
J Am Med Dir Assoc. 2021 Aug;22(8):1574-1580.e8
pubmed: 34174196
Nephrol Dial Transplant. 2020 Nov 1;35(11):1973-1983
pubmed: 33151337
Eur J Epidemiol. 2021 Mar;36(3):287-298
pubmed: 33704634
Ther Apher Dial. 2021 Oct;25(5):544-550
pubmed: 33040443
Front Cell Infect Microbiol. 2022 Jan 18;11:781429
pubmed: 35118007
Clin J Am Soc Nephrol. 2022 Mar;17(3):395-402
pubmed: 35144970
Clinics (Sao Paulo). 2020 Jun 03;75:e1983
pubmed: 32520225
Kidney Blood Press Res. 2021;46(2):250-256
pubmed: 33774645
BMJ. 2022 Mar 9;376:e069761
pubmed: 35264324
Nephrol Dial Transplant. 2022 Sep 22;37(10):1868-1878
pubmed: 34788858
Nephrol Dial Transplant. 2022 Sep 22;37(10):1944-1950
pubmed: 35767848
Am J Transplant. 2022 Aug;22(8):2077-2082
pubmed: 35294799
Lancet Infect Dis. 2021 Nov;21(11):1518-1528
pubmed: 34171232
World Med Health Policy. 2022 Sep;14(3):507-527
pubmed: 34226854
Scand J Urol Nephrol. 2004;38(4):332-9
pubmed: 15669594
Nephrol Dial Transplant. 2022 Oct 19;37(11):2253-2263
pubmed: 35927791
Kidney Int. 2020 Dec;98(6):1568-1577
pubmed: 33137341
Am J Transplant. 2021 Aug;21(8):2762-2773
pubmed: 33811777
Kidney Int. 2020 Dec;98(6):1540-1548
pubmed: 32979369
Clin Microbiol Infect. 2022 Feb;28(2):163-177
pubmed: 35020589
BMJ. 2022 Mar 2;376:e068632
pubmed: 35236664
J Clin Med. 2020 Oct 28;9(11):
pubmed: 33126481
Clin J Am Soc Nephrol. 2022 Jun;17(6):843-850
pubmed: 35649718
Kidney Int. 2020 Jul;98(1):27-34
pubmed: 32437770
Microorganisms. 2021 Dec 21;10(1):
pubmed: 35056453
Kidney Int Rep. 2022 Sep;7(9):2091-2096
pubmed: 35757188
Nature. 2021 Nov;599(7883):114-119
pubmed: 34488225
Nephrol Dial Transplant. 2020 Dec 16;:
pubmed: 33326038
Lancet Infect Dis. 2022 Jan;22(1):35-42
pubmed: 34461056
Nephrol Dial Transplant. 2022 Jul 26;37(8):1566-1575
pubmed: 35544087